Calcitonin Salmon

Quick links

Choose a section

Quick links to important sections

Advertisements

Calcitonin Salmon

Selected form

Advertisements
Advertisements

Overview of Calcitonin Salmon

Property Description
Active ingredient Calcitonin Salmon (salmon calcitonin)
Form Injectable Solution, Nasal Spray
Pharmacological class Calcium Regulator, Bone Resorption Inhibitor
General purpose Helps preserve bone mass and regulates calcium levels
Origin Synthetic Peptide Derivative

What Type of Medicine is Calcitonin Salmon?

Calcitonin Salmon is a synthetic polypeptide hormone classified as a bone resorption inhibitor and potent calcium regulator, clinically recognized for its influence on skeletal integrity. The active ingredient is a 32-amino acid synthetic peptide that structurally mimics the calcitonin hormone found in salmon. This synthetic version is utilized in therapeutic contexts because it possesses a greater potency and a longer duration of action when administered to humans compared to naturally occurring human calcitonin. This potency is a key differentiating factor which defines its role in managing mineral balance. The drug is supplied as an aqueous solution for systemic use, typically provided as an injectable solution or in a fine mist for intranasal administration, offering flexible delivery routes based on therapeutic need.

The General Purpose of Calcitonin Salmon

The fundamental role of Calcitonin Salmon is to control calcium metabolism by directly suppressing the activity of bone-removing cells. It achieves this by binding to specific receptors on osteoclasts, thereby inhibiting their ability to break down existing bone tissue and release calcium into the bloodstream. Calcitonin Salmon manages conditions related to excessive bone loss and hypercalcemia due to its rapid inhibitory effect on osteoclastic activity. The medicine is utilized for managing calcium and bone density imbalances. By preserving bone mass and regulating calcium concentrations, the drug serves its general purpose of stabilizing the skeletal structure and maintaining internal mineral balance, particularly in scenarios where rapid and effective suppression of bone resorption is required.

Regulatory References

  1. Calcitonin - StatPearls - NCBI Bookshelf
  2. Calcitonin Salmon Nasal Spray: MedlinePlus Drug Information
Advertisements

What side effects are possible with Calcitonin Salmon?

Possible Side Effects and Safety Information

The officially documented safety profile for Calcitonin Salmon is defined by specific categories of adverse reactions and long-term exposure patterns established in regulatory documents. Adverse reactions are classified by frequency, primarily affecting the gastrointestinal system and administration sites.

Frequency-Classified Adverse Reactions

Classification Examples of Reactions
Very Common Nausea, Vomiting (especially with injection), Rhinitis, Nasal irritation/dryness (nasal spray)
Common Headache, Dizziness, Flushing of the face and hands, Diarrhea, Arthralgia, Injection site reactions

These frequently reported events are separated from less common but more clinically significant safety concerns.

Serious Adverse Reactions and Safety Constraints

Regulatory documents highlight the potential for severe Hypersensitivity Reactions, including anaphylaxis, which are critical safety concerns. Furthermore, regulatory agencies have documented a statistically significant Increased Risk of Malignancy (solid tumors) specifically associated with the long-term use of the Calcitonin Salmon nasal spray formulation.

Several safety constraints are officially defined. Pre-existing hypocalcemia must be corrected before therapy initiation. Nausea and vomiting are often noted as being more frequent at the start of treatment, while the malignancy risk is directly associated with duration of exposure. The formation of neutralizing antibodies has also been observed, which may lead to a reduced biological response.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Calcitonin Salmon overdose focuses strictly on the consequences of an exaggerated pharmacological effect, namely the significant reduction of serum calcium. The primary physiological system affected is calcium metabolism.

An overdose may result in hypocalcemia, which is an abnormally low level of calcium in the blood. Documented clinical manifestations that accompany overexposure include pronounced nausea and vomiting. In severe cases, the consequence of acute hypocalcemia can escalate to tetany (involuntary muscle contractions) and potential seizure activity. Overexposure to the injectable form carries a specific risk of progressing to hypocalcemic tetany.

Regulatory documents mandate that any suspected overdose requires the patient to seek immediate medical attention. The required emergency response involves immediate symptomatic and supportive management. As a procedural step, provisions must be readily available for the administration of intravenous calcium to counteract severe hypocalcemia. Furthermore, patient condition and serum calcium levels require close monitoring during the overdose event. It is officially documented that no specific antidote is known for Calcitonin Salmon overexposure.

Advertisements

Therapeutic Uses of Calcitonin Salmon

What Calcitonin Salmon Treats: Main Uses and Benefits

Calcitonin salmon is generally used for managing symptoms related to systemic imbalance and conditions characterized by periods of heightened symptoms in contexts involving systemic or localized discomfort.

Calcitonin salmon (injection) is indicated for use across domains where additional symptomatic support is needed for three situations involving certain distressing symptoms, including the treatment of symptomatic Paget’s disease of bone, the early treatment of hypercalcemia, and the treatment of postmenopausal osteoporosis (nasal spray formulation).

In these contexts, the medication may assist with contributing to easing discomfort and is relevant for managing symptoms that create noticeable physiological strain. For patients, this contributes to improved comfort during periods of heightened symptoms and may assist with maintaining a sense of stability when symptoms are more noticeable. The overall approach is relevant when supportive symptom management is appropriate in clinical settings that involve acute or unstable symptom patterns.

“It plays a role in managing acute phases of physiological imbalance where short-term symptomatic assistance is needed.”

Quick Fact: Support for Symptom Clusters The use of calcitonin salmon is commonly used to help with managing symptom clusters that may become intense or disruptive, involving episodic or fluctuating manifestations.

Regulatory References

  1. Label: CALCITONIN SALMON injection, solution - DailyMed
Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Calcitonin Salmon?

Eligibility for Calcitonin Salmon is strictly defined by regulatory documents, determining which populations may use the medicine and which are prohibited or restricted.

Populations Prohibited or Restricted

The medicine is contraindicated for patients with a known hypersensitivity to calcitonin-salmon or any component of the product. Use is also contraindicated if a patient has pre-existing hypocalcaemia, which must be corrected before treatment initiation.

Category Eligibility Status (Official Regulatory Statement)
Pediatric Population Safety and efficacy have not been established
Pregnancy/Lactation Not indicated for use in females of reproductive potential or nursing mothers
Conditional Use For certain indications (e.g., Paget's disease), use is restricted to patients who cannot use or have not responded to alternative treatments
Metabolic Conditions Other mineral disorders, such as Vitamin D deficiency, must be effectively treated prior to therapy

Eligible Populations

Calcitonin Salmon is generally indicated for adults (18 years and older). Use is officially permitted for those with hepatic or renal impairment, as regulatory data shows no evidence of reduced tolerability or altered dosage requirements in these groups. Older adults do not have specific age-related limitations noted in official prescribing information.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information regarding drug interactions for Calcitonin Salmon is specific and limited, largely because formal drug interaction studies have not been conducted according to prescribing information. Consequently, no specific interactions involving Cytochrome P450 (CYP) enzymes or drug transporters are documented.


Documented Pharmacodynamic and Clearance Interactions

Interaction Type Interacting Substance Official Regulatory Description
Altered Clearance Lithium Co-administration may lead to a reduction in plasma Lithium concentrations due to increased urinary clearance of Lithium. Monitoring and potential dose adjustment are officially noted as necessary.
Pharmacodynamic Effect Diphosphonates (e.g., Bisphosphonates) Prior or concurrent use in the context of Paget's disease of bone may reduce the expected anti-resorptive response to Calcitonin Salmon.

Interaction Constraints

The interaction profile does not include mandatory time-separation rules for co-administered medicines. Furthermore, government regulatory labels for both injectable and nasal spray formulations do not document specific interactions with food, alcohol, herbal products, or supplements. Metabolic clearance of the medicine itself is noted as significantly lower in patients with end-stage renal failure, which is a pharmacokinetic consideration relevant to overall drug exposure.

Advertisements

Mechanism of Action

Molecular Mechanism: Calcitonin Salmon

The mechanism of Calcitonin Salmon is based on its selective binding to the Calcitonin Receptor (CTR), a specialized receptor found primarily on cells responsible for bone and mineral regulation.


Direct Inhibition of Osteoclast-Mediated Bone Resorption

The core action involves the drug acting as an agonist on the CTR found on bone-removing cells, the osteoclasts. This receptor activation triggers an immediate intracellular cascade that rapidly disrupts the osteoclast's internal structure and motility, causing the cell to detach from the bone surface. This physiological change abruptly leads to the cessation of resorptive activity against bone matrix, consequently suppressing the release of calcium and phosphate from the skeleton into the bloodstream.


Dual Control of Mineral Balance via Kidney Modulation

In addition to its skeletal effect, the drug engages CTRs located in the kidney tubules, resulting in a direct physiological consequence on mineral excretion. Activation of these renal receptors decreases the kidney's ability to reabsorb filtered electrolytes, particularly calcium and phosphate. This combined effect of suppressing skeletal release and simultaneously increasing renal excretion produces a net physiological consequence of reduced calcium concentration in serum.


Secondary Modulation of Central Nociceptive Pathways

Calcitonin Salmon also acts on specific central nervous system (CNS) pathways, leading to a secondary influence on nociceptive signal transmission that is independent of its action on bone. This mechanism is thought to involve the drug’s influence on central receptor systems, such as certain serotonergic pathways, which modulates the transmission and processing of these signals in the spinal cord and brain.

Advertisements

Dosage and Administration Information

How to Use Calcitonin Salmon

Calcitonin Salmon is administered using specific methods and schedules based on the condition being treated. The two primary forms are an injectable solution and an intranasal spray.


Routes and Forms of Administration

The medicine is administered through the following routes:

  • Intranasal: Via a single-spray nasal device.
  • Parenteral: Subcutaneous (SC) injection, Intramuscular (IM) injection, or slow Intravenous (IV) infusion (primarily for hypercalcemia).

Dosage Regimens

Dosing varies based on the specific formulation, the route of administration, and the condition being treated.

Indication Dosage Form & Route Standard Frequency Dose Range
Postmenopausal Osteoporosis Nasal Spray (Intranasal) Once Daily 200 IU (1 spray)
Paget's Disease Injection (SC or IM) Daily, or every 1–3 days 50 IU to 100 IU
Hypercalcemia Injection (SC or IM/IV) Every 6 or 12 hours 4 IU/kg to 8 IU/kg

Key Administration Instructions

Nasal Spray Use: The full daily dose is administered as one spray into one nostril only. It is necessary to alternate nostrils daily (e.g., left nostril one day, right nostril the next). The pump must be primed prior to the first use.

Injection Use: If the volume of the injection is large (exceeding 2 mL), the intramuscular route is typically used, and the dose should be distributed across multiple sites. Administration may be timed at bedtime to potentially reduce the occurrence of nausea.

Coadministration: For chronic conditions such as osteoporosis, Calcitonin Salmon is typically used in conjunction with 1000 mg of elemental calcium and 400 IU of Vitamin D per day.

Advertisements

Recent Clinical Evidence

Research Evidence Overview: Calcitonin Salmon


Evidence for Use in Paget's Disease of Bone

Calcitonin Salmon was studied for its use in individuals diagnosed with symptomatic Paget’s Disease of Bone, which is a condition characterized by high bone turnover. The research involved generally small clinical studies and observational data on adult patients with symptomatic forms of the condition. Outcomes related to physical discomfort and changes in systemic markers of bone turnover were monitored.

Findings describe patterns where measurements of biochemical markers of bone breakdown were collected during the study period. Studies reported observations that the measured changes did not always persist over time with continued use. The overall evidence base relies on earlier, smaller clinical studies, and the long-term outcomes are not fully established.


Evidence for Use in Acute Hypercalcemia

Research has explored the use of Calcitonin Salmon in acute scenarios, specifically in conditions associated with high calcium levels (hypercalcemia). These studies focused on patients who required rapid calcium management. The primary research monitored the rate and magnitude of decrease in elevated serum calcium levels over a period of hours or days.

Data show patterns related to changes in calcium concentrations, observed within a short timeframe. The observed changes were reported to be transient, with the measured response often diminishing after approximately 48 hours of use. Evidence is limited regarding large, direct comparisons of this medication against other treatments in acute settings.


Evidence for Use in Postmenopausal Osteoporosis

Research has studied Calcitonin Salmon nasal spray in postmenopausal women with established osteoporosis. This research involved large-scale, controlled trials, including a major placebo-controlled study that monitored outcomes over five years.

Findings from the long-term trial described patterns where the incidence of new vertebral fracture was observed to be lower in the group that received a specific daily dose. Studies also reported observations related to patterns of Bone Mineral Density (BMD) at the lumbar spine. However, findings were mixed when different dosages were compared, indicating that a clear dose-response relationship was not established.


Long-Term Follow-up and Study Durability

The research for the postmenopausal osteoporosis indication involved a follow-up period of up to five years. This evidence helps contextualize symptom patterns and fracture risk over an extended period. However, this study experienced a high rate of patient discontinuation, and no evidence has been reported to characterize the medication’s influence on non-vertebral or hip fracture risk.

Key Studies & References

  1. Calcitonin Dosing for Hypercalcemia of Malignancy (Study on efficacy and dosing protocol)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Calcitonin Salmon (FAQ)


Q: Is Calcitonin Salmon the same as human calcitonin?

A: Calcitonin Salmon is a synthetic polypeptide (a small protein) that is made to resemble the calcitonin hormone found in salmon. Although it works similarly to human calcitonin in the body, its chemical structure is different. Official documents clarify this distinction, which is why the drug is specified as 'salmon' calcitonin.

Q: How quickly does Calcitonin Salmon start to have an effect?

A: Regulatory documents describe different timeframes depending on the condition and route of administration. For instance, when used by injection for acutely high calcium levels, an initial effect can be seen within approximately two hours. For the nasal spray, the medicine typically reaches its peak concentration in the bloodstream within 31 to 39 minutes after use.

Q: Can Calcitonin Salmon injections be painful?

A: Yes, injection site reactions are commonly reported when using the injectable form of this medicine. According to official adverse reactions data, these local reactions can include pain, redness, swelling, or itching at or near the site of the administration.

Q: Is a metallic taste common after using the nasal spray?

A: Taste disturbances, including sensations such as an unpleasant, salty, or metallic taste, are listed in official documents as a less common side effect associated with the nasal spray formulation. It is one of the ways patients may experience the medicine after administration.

Q: Does Calcitonin Salmon treat low bone density, or is it just for pain?

A: The medicine has two distinct actions that address both bone structure and pain signals. It is officially indicated for the treatment of certain bone conditions like postmenopausal osteoporosis and Paget's disease. Separately, official documents describe a mechanism where it influences central pain signals, which may help relieve bone pain associated with vertebral fractures.

Q: Is Calcitonin Salmon a hormone replacement therapy?

A: Calcitonin Salmon is not classified as a traditional hormone replacement therapy (HRT). It is categorized as a Calcitonin Receptor Agonist. This means it is a man-made substance that acts upon specific receptors in the body, mimicking the effects of the naturally occurring calcitonin hormone.

Q: Can Calcitonin Salmon affect blood pressure?

A: Flushing, which is a common side effect described in official product information, involves a sensation of warmth and reddening of the face or hands. While generalized flushing is listed, official regulatory documents do not list specific changes in blood pressure as a commonly reported side effect or a routine monitoring concern.

Q: What are the most common reasons a doctor prescribes Calcitonin Salmon?

A: The official uses (indications) for Calcitonin Salmon are the treatment of Paget's disease of bone, certain cases of high calcium levels (hypercalcemia), and postmenopausal osteoporosis. For osteoporosis, it is often reserved for individuals for whom other approved treatments are not suitable or recommended.

Q: Why is Calcitonin Salmon called 'salmon' calcitonin?

A: Official descriptive texts explain that the drug is based on the polypeptide structure that was originally identified and isolated from the ultimobranchial gland of the salmon fish. The synthetic version used as a medicine maintains this unique 'salmon' designation.

Q: Do you have to take Calcitonin Salmon forever, or is it a short course?

A: Official prescribing information notes limitations on the duration of treatment, particularly for chronic conditions like osteoporosis. For Paget’s disease, treatment is usually stopped once a patient has responded to the therapy, and official guidelines often recommend limiting use to a maximum of six months.

Q: What kind of studies have been done on the long-term use of Calcitonin Salmon?

A: Clinical trials and subsequent data analyses have specifically examined the effects of using Calcitonin Salmon over a prolonged period. The data from these studies indicated an overall incidence of malignancies (cancers) that was higher among patients receiving the medicine compared to those on placebo.

Q: Is it normal to feel dizzy or lightheaded after using the nasal spray?

A: Dizziness is listed in official adverse reaction data as a less common side effect. The EMA label notes that dizziness may occur, and official product information indicates this effect has the potential to temporarily impair ability to drive or operate machinery.

Q: Why does the packaging say 'synthetic' Calcitonin Salmon?

A: The term 'synthetic' is used in the product description to indicate that the polypeptide medicine is chemically manufactured in a laboratory setting. This confirms that, while it mirrors the structure of the salmon hormone, it is not extracted directly from animals.

Q: Can Calcitonin Salmon interact with thyroid medications?

A: Official regulatory labels generally state that formal studies designed to detect drug interactions with calcitonin-salmon, including interactions with thyroid medications, have not been widely conducted. As a result, only specific interactions, such as those with Lithium, are documented in official prescribing information.

Q: What is the maximum amount of time people usually use Calcitonin Salmon?

A: Regulatory information notes that, due to potential long-term safety concerns, the duration of therapy for chronic uses like osteoporosis should be limited to the shortest effective time period. For Paget's disease, the maximum recommended period of use is typically six months.

Q: Do older adults tolerate Calcitonin Salmon well?

A: Regulatory documents note that unwanted side effects, such as nasal irritation or a stuffy/runny nose, have been reported to occur more frequently in elderly patients using the nasal spray formulation.

Q: Is it possible to become allergic to Calcitonin Salmon after repeated use?

A: Yes, serious hypersensitivity (allergic) reactions, including anaphylaxis, have been reported in connection with Calcitonin Salmon. For patients where sensitivity is suspected, regulatory labels mention that a skin test may be considered prior to starting treatment.

Q: Can Calcitonin Salmon affect a person's mood or cause depression?

A: Mental depression is listed in official adverse reaction data as a less common or rare side effect associated with the use of Calcitonin Salmon. This is not reported as a typical side effect but is noted in regulatory information.

Q: Is there a generic version of Calcitonin Salmon available?

A: Generic versions of the injectable form are available and are listed in official FDA drug records. The availability status of a generic nasal spray formulation may vary.

Q: Can Calcitonin Salmon be used by men with osteoporosis?

A: Official indications show that the injectable form is specifically approved for the treatment of osteoporosis in men. However, the nasal spray formulation is typically approved only for postmenopausal osteoporosis in women.

Q: Are there any specific groups of people who should definitely avoid Calcitonin Salmon?

A: The medicine is contraindicated in people with a known hypersensitivity or severe allergic reaction to calcitonin-salmon or any of the product's non-active ingredients. Pre-existing hypocalcemia, which is an abnormally low level of calcium in the blood, must also be corrected before starting use.

Q: Can Calcitonin Salmon cause flushing or redness of the face?

A: Yes, flushing is a commonly reported side effect, especially with the injectable form. This involves a sensation of warmth and reddening of the face or hands shortly after administering the medicine.

Q: Are there any food or drink interactions with Calcitonin Salmon?

A: Official regulatory labels state that formal drug interaction studies with food, alcohol, or herbal products have not been documented. Therefore, there are no specific warnings against using the medicine with food or drink listed in the interaction profile.

Q: Are there any serious, but rare, side effects I should know about?

A: The reported serious side effects include severe allergic reactions, the potential for hypocalcemia (low blood calcium), and a noted overall increased incidence of malignancy (cancer) in certain clinical trial data.

Q: Is it safe to drive or operate machinery while using Calcitonin Salmon?

A: Official product information cautions that the medicine may cause fatigue, dizziness, and visual disturbances. Official product information states that if these effects occur, the ability to drive or operate machinery may be temporarily impaired.

Q: Is the nasal spray irritating to the nose or sinuses?

A: Yes, adverse reactions specific to the nose are commonly reported with the nasal spray. These can include rhinitis (runny nose), epistaxis (nosebleeds), general nasal irritation, and potential changes to the nasal lining (mucosal alterations or ulceration).

Q: What are common patient concerns about the injectable form?

A: Official adverse events data indicates that common concerns related to the injectable form include injection site reactions (such as pain, redness, or swelling), as well as systemic effects like nausea, vomiting, and flushing (warmth and redness of the face or hands).

Advertisements

How should Calcitonin Salmon be stored and disposed of?

How to Store and Dispose of Calcitonin Salmon

Official regulatory information requires specific handling and storage conditions to maintain the stability of Calcitonin Salmon, which is available as both an injectable solution and a nasal spray.

Storage Category Requirement
Unopened Product Refrigerate at 2 C to 8 C (36 F to 46 F). Do not freeze
In-Use Stability Discard the Nasal Spray 30–35 days after initial use. Discard the multi-dose Injection vial 14 days after the first dose.
Protection Keep the medicine out of the sight and reach of children. The Nasal Spray must be protected from light in its original carton.
Disposal Dispose of used needles and syringes in an FDA-cleared sharps container. Discard all unused or expired product according to local pharmaceutical waste regulations.

The Nasal Spray must be stored upright at controlled room temperature after its first use, and the product must always be inspected visually for discoloration or particles before use. These mandatory constraints define how the medicine must be protected and discarded.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Calcitonin Salmon found in:

A-Z Index: